First oral GLP-1 receptor agonist approved for weight loss - PubMed
4 hours ago
- #weight loss
- #FDA approval
- #GLP-1 receptor agonist
- FDA approved the first oral GLP-1 receptor agonist for weight loss, based on positive phase III OASIS 4 trial results.
- The oral form of Wegovy will be sold in the U.S. by Novo Nordisk, starting at $149 per month.
- This approval represents a significant advancement in weight loss treatment options, offering an alternative to injectable GLP-1 agonists.